Experimental Hepatitis C Drug Shows Promise in Study

Boston (DbTechNo) – Results of a new clinical trial are positive for an experimental drug to treat hepatitis C.

The drug, called ANA598 is in its experimental phase and is manufactured by Anadys Pharmaceuticals.

The study pitted patients given the drug against those given a placebo, with the results proving without a doubt that the drug works.

After only 4 weeks of treatment, 56% of patients with hepatitis C who received the drug showed no signs of the virus in their blood, compared to 20% of the group on placebo treatment.

The only main side effect associated with the drug was a rash.

News of the positive drug study has done wonders for the company’s shares sending them up by 9 percent.

• Share
• Tweet
• "&title=""">